ArticleFrontiers in oncology2026
Salidroside inhibits glioma cell migration and proliferation through CYP2E1-neuroglobin-cytochrome c mediated redox axis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GB) represents one of the most aggressive primary brain tumors characterized by poor prognosis, high relapse and resistance to conventional therapies. Salidroside, a naturally occurring glucoside derived from Rhodiola rosea, has been reported to exhibit pro-apoptotic and anti-proliferative properties across multiple cancer models; however, its mechanistic basis in glioma and its therapeutic potential remain incompletely characterized. Methods: Neuroglobin (Ngb) protein expression was analyzed in 101 glioma brain tissue specimens and 5 normal brain tissues by western blot and immunohistochemical staining. In silico analyses of oxidized and reduced state of Ngb with salidroside was performed along with pharmacokinetics and toxicity predictions to computationally evaluate possible binding interactions and drug-like properties. Further, to determine the underlying mechanisms, Results: Ngb expression in glioma tissues samples significantly downregulated with increasing tumour grade as determined by immunoreactivity and western blot analysis. In-silico analyses predicted a possible interaction of salidroside with reduced state of Ngb, Conclusion: Salidroside exerts multi-faceted anti-cancer effects in glioblastoma cells, potentially involving upregulation of Ngb levels in glioma cells, modulation of redox homeostasis, mitochondrial integrity and intrinsic apoptotic signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.